Summary: A new study reveals that 12-18 months after hospitalization for COVID-19, patients show significant cognitive decline comparable to 20 years of aging. MRI scans and blood tests also show brain injury markers and reduced brain volume in these patients. The findings suggest that COVID-19 has lasting effects on brain health, even in those without neurological complications.
Key Facts:
- COVID-related cognitive decline equals about 20 years of normal aging.
- Brain scans show reduced volume and injury in key areas after COVID-19.
- Both neurological and non-neurological patients experienced cognitive deficits.
Source: University of Liverpool
New steps have been taken towards a better understanding of the immediate and long-term impact of COVID-19 on the brain in the UK’s largest study to date.
Published in Nature Medicine, the study from researchers led by the University of Liverpool alongside King’s College London and the University of Cambridge as part of the COVID-CNS Consortium shows that 12-18 months after hospitalisation due to COVID-19, patients have worse cognitive function than matched control participants.
Importantly, these findings correlate with reduced brain volume in key areas on MRI scans as well as evidence of abnormally high levels of brain injury proteins in the blood.
Strikingly, the post-COVID cognitive deficits seen in this study were equivalent to twenty years of normal ageing. It is important to emphasise that these were patients who had experienced COVID, requiring hospitalisation, and these results shouldn’t be too widely generalised to all people with lived experience of COVID.
However, the scale of deficit in all the cognitive skills tested, and the links to brain injury in the brain scans and blood tests, provide the clearest evidence to date that COVID can have significant impacts on brain and mind health long after recovery from respiratory problems.
The work forms part of the University of Liverpool’s COVID-19 Clinical Neuroscience Study (COVID-CNS), which addresses the critical need to understand the biological causes and long-term outcomes of neurological and neuropsychiatric complications in hospitalised COVID-19 patients.
Study author Dr Greta Wood from the University of Liverpool said: “After hospitalisation with COVID-19 many people report ongoing cognitive symptoms often termed ‘brain fog’.
“However, it has been unclear as to whether there is objective evidence of cognitive impairment and, if so, is there any biological evidence of brain injury; and most importantly if patients recover over time.
“In this latest research, we studied 351 COVID-19 patients who required hospitalisation with and without new neurological complications.
“We found that both those with and without acute neurological complications of COVID-19 had worse cognition than would be expected for their age, sex and level of education, based on 3,000 control subjects.”
Corresponding author Professor Benedict Michael, Professor of Neuroscience at the University of Liverpool said: “COVID-19 is not a condition simply of the lung. Often those patients who are most severely affected are the ones who have brain complications.
“These findings indicate that hospitalisation with COVID-19 can lead to global, objectively measurable cognitive deficits that can be identified even 12-18 months after hospitalisation.
“These persistent cognitive deficits were present in those hospitalised both with and without clinical neurological complications, indicating that COVID-19 alone can cause cognitive impairment without a neurological diagnosis having been made.
“The association with brain cell injury biomarkers in blood and reduced volume of brain regions on MRI indicates that there may be measurable biological mechanisms underpinning this.
“Now our group is working to understand whether the mechanisms that we have identified in COVID-19 may also be responsible for similar findings in other severe infections, such as influenza.”
Professor Gerome Breen from King’s College London said: “Long term research is now vital to determine how these patients recover or who might worsen and to establish if this in unique to COVID-19 or a common brain injury with other infections.
“Significantly our work can help guide the development of both similar studies in those with Long-COVID who often have much milder respiratory symptoms and also report cognitive symptoms such as ‘brain fog’ and also to develop therapeutic strategies.”
More about COVID-CNS
The COVID-19 Clinical Neuroscience Study (COVID-CNS) is a £2.3m UKRI study jointly led by researchers at the University of Liverpool and King’s College London. Acute neurological and neuropsychiatric complications of COVID-19 affect up to 20-30% of hospitalised patients.
Researchers are studying the acute neurological and neuropsychiatric effects of infection, the long-term clinical and cognitive outcomes, and crucially determining the underlying biological processes driving this through better understanding of brain injury, immune responses and genetic risk factors.
Funding: This publication was funded by the UK Research and Innovation (UKRI) grant COVID-CNS and is supported through the national NIHR BioResource and the NIHR Cambridge Biomedical Research Centre.
We thank NIHR BioResource team and patient volunteers for their participation and the Patient and Public Involvement Panel who guided each stage.
About this cognition, COVID, and aging research news
Author: Jennifer Morgan
Source: University of Liverpool
Contact: Jennifer Morgan – University of Liverpool
Image: The image is credited to Neuroscience News
Original Research: Closed access.
“Post-hospitalisation COVID-19 cognitive deficits at one year are global and associated with elevated brain injury markers and grey matter volume reduction” by Greta Wood et al. Nature Medicine
Abstract
Post-hospitalisation COVID-19 cognitive deficits at one year are global and associated with elevated brain injury markers and grey matter volume reduction
The spectrum, pathophysiology, and recovery trajectory of persistent post-COVID-19 cognitive deficits are unknown, limiting our ability to develop prevention and treatment strategies.
We report the one-year cognitive, serum biomarker, and neuroimaging findings from a prospective, national study of cognition in 351 COVID-19 patients who had required hospitalisation, compared to 2,927 normative matched controls.
Cognitive deficits were global and associated with elevated brain injury markers, and reduced anterior cingulate cortex volume one year after COVID-19. The severity of the initial infective insult, post-acute psychiatric symptoms, and a history of encephalopathy were associated with greatest deficits.
There was strong concordance between subjective and objective cognitive deficits. Longitudinal follow-up in 106 patients demonstrated a trend toward recovery.
Together, these findings support the hypothesis that brain injury in moderate to severe COVID-19 may be immune-mediated, and should guide the development of therapeutic strategies.
